AR021798A1 - Procedimiento para tratar mujeres que sufren o son susceptibles a enfermedades de transmision sexual y uso de antigenos derivados o asociados con patogenoscausantes de std, para preparar vacunas aplicables en dicho procedimiento. - Google Patents

Procedimiento para tratar mujeres que sufren o son susceptibles a enfermedades de transmision sexual y uso de antigenos derivados o asociados con patogenoscausantes de std, para preparar vacunas aplicables en dicho procedimiento.

Info

Publication number
AR021798A1
AR021798A1 ARP990104534A AR021798A1 AR 021798 A1 AR021798 A1 AR 021798A1 AR P990104534 A ARP990104534 A AR P990104534A AR 021798 A1 AR021798 A1 AR 021798A1
Authority
AR
Argentina
Prior art keywords
procedure
pathogenosauses
std
suffer
susceptible
Prior art date
Application number
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR021798(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR021798A1 publication Critical patent/AR021798A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un procedimiento para administrar una vacuna a mujeres, con el fin de prevenir o tratar infecciones asociadas con patogenos que provocanenfermedades de trasmision sexual. La vacuna comprende uno o más antígenos para la prevencion o tratamiento de enfermedades de transmision sexual, por ejemplo,la glicoproteína D de HSV o un fragmento inmunologico de la misma, y un adyuvante, especialmente un adyuvante de induccion de TH-1. También se describe el usode los componentes de vacuna para la formulacion de una composicion de vacuna para la prevencion o tratamiento de enfermedades de transmision sexual.
ARP990104534 1998-09-11 1999-09-09 Procedimiento para tratar mujeres que sufren o son susceptibles a enfermedades de transmision sexual y uso de antigenos derivados o asociados con patogenoscausantes de std, para preparar vacunas aplicables en dicho procedimiento. AR021798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use

Publications (1)

Publication Number Publication Date
AR021798A1 true AR021798A1 (es) 2002-08-07

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104534 AR021798A1 (es) 1998-09-11 1999-09-09 Procedimiento para tratar mujeres que sufren o son susceptibles a enfermedades de transmision sexual y uso de antigenos derivados o asociados con patogenoscausantes de std, para preparar vacunas aplicables en dicho procedimiento.

Country Status (29)

Country Link
EP (1) EP1109574B1 (es)
JP (1) JP2002524532A (es)
KR (1) KR100777896B1 (es)
CN (2) CN101130070A (es)
AR (1) AR021798A1 (es)
AT (1) ATE392214T1 (es)
AU (1) AU744989B2 (es)
BR (1) BR9913630A (es)
CA (1) CA2343399C (es)
CO (1) CO5090882A1 (es)
CY (1) CY1108147T1 (es)
CZ (1) CZ302808B6 (es)
DE (1) DE69938555T2 (es)
DK (1) DK1109574T3 (es)
ES (1) ES2304068T3 (es)
GB (1) GB9819898D0 (es)
HK (1) HK1037978A1 (es)
HU (1) HUP0104297A3 (es)
IL (1) IL141843A0 (es)
MY (1) MY122216A (es)
NO (1) NO329522B1 (es)
NZ (1) NZ510425A (es)
PL (1) PL199545B1 (es)
PT (1) PT1109574E (es)
SI (1) SI1109574T1 (es)
TR (1) TR200100948T2 (es)
TW (1) TWI225790B (es)
WO (1) WO2000015255A1 (es)
ZA (1) ZA200101987B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
JP6109165B2 (ja) * 2011-07-01 2017-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヘルペスウイルスワクチンおよび使用方法
SG11201700061PA (en) 2014-07-07 2017-02-27 Prophylaxis LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CA3010905A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
HU219056B (hu) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
PL346651A1 (en) 2002-02-25
EP1109574B1 (en) 2008-04-16
PL199545B1 (pl) 2008-09-30
HK1037978A1 (en) 2002-03-01
AU5975299A (en) 2000-04-03
HUP0104297A2 (hu) 2002-03-28
EP1109574A1 (en) 2001-06-27
SI1109574T1 (sl) 2008-08-31
CA2343399C (en) 2010-08-03
CO5090882A1 (es) 2001-10-30
IL141843A0 (en) 2002-03-10
DK1109574T3 (da) 2008-06-30
PT1109574E (pt) 2008-06-12
GB9819898D0 (en) 1998-11-04
JP2002524532A (ja) 2002-08-06
DE69938555D1 (de) 2008-05-29
CY1108147T1 (el) 2014-02-12
CZ302808B6 (cs) 2011-11-23
AU744989B2 (en) 2002-03-07
CA2343399A1 (en) 2000-03-23
ZA200101987B (en) 2002-05-09
CN101130070A (zh) 2008-02-27
CZ2001887A3 (cs) 2001-10-17
ES2304068T3 (es) 2008-09-01
NO20011193L (no) 2001-05-09
ATE392214T1 (de) 2008-05-15
CN1325311A (zh) 2001-12-05
TWI225790B (en) 2005-01-01
NZ510425A (en) 2003-04-29
NO20011193D0 (no) 2001-03-08
DE69938555T2 (de) 2009-06-10
KR20010075049A (ko) 2001-08-09
HUP0104297A3 (en) 2004-10-28
WO2000015255A1 (en) 2000-03-23
NO329522B1 (no) 2010-11-01
TR200100948T2 (tr) 2001-07-23
MY122216A (en) 2006-03-31
BR9913630A (pt) 2001-05-22
KR100777896B1 (ko) 2007-11-27

Similar Documents

Publication Publication Date Title
AR021798A1 (es) Procedimiento para tratar mujeres que sufren o son susceptibles a enfermedades de transmision sexual y uso de antigenos derivados o asociados con patogenoscausantes de std, para preparar vacunas aplicables en dicho procedimiento.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
WO2003009812A3 (en) Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
ES2170234T3 (es) Vacuna contra el virus prrs (sindrome reproductor y respiratorio porcino).
AU4358801A (en) Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
DK1326636T3 (da) Vaccinesammensætning
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
AR025749A1 (es) Vacunas
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
HK1005541A1 (en) Treatment of helicobacter associated gastroduodenal disease
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
KR970701209A (ko) 헬리코박터 감염의 치료 또는 예방용 항원제제(antigenic preparation for treatment or prevention of helicobacter infection)
PT1135020E (pt) Tratamentos para a loque
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
NO20012634L (no) Nye kreftbehandlinger
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC

Legal Events

Date Code Title Description
FB Suspension of granting procedure